New drug combo targets deadly brain tumors in early trial
NCT ID NCT06806228
First seen Nov 18, 2025 · Last updated May 01, 2026 · Updated 17 times
Summary
This early-phase study tests whether adding the experimental drug S-Gboxin to standard radiation and chemotherapy can help control glioblastoma and diffuse midline glioma, two aggressive brain cancers. About 10 participants whose cancer has returned or worsened will receive the combination. The study uses brain scans to measure changes in tumor activity and size, and tracks survival and side effects over 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kazakh Institute of Oncology and Radiology
Almaty, 490 078, Kazakhstan
-
National Cancer Institute
Kyiv, 33/43, Ukraine
-
Tbilisi Cancer Centre
Tbilisi, 0198, Georgia
Conditions
Explore the condition pages connected to this study.